Hamps Bio Ltd FY2026 Financial Results

Consolidated Loss: ₹0.74 crore
Revenue Growth: 27.7%

Reader Takeaway: Revenue growth is positive, but the shift to a lossmaking position is a concern.

What just happened

Hamps Bio Ltd announced its audited standalone and consolidated financial results for the fiscal year ended March 31, 2026. The company reported a consolidated revenue from operations of ₹8.47 crore, marking a 27.7% increase from ₹6.67 crore in the previous fiscal year. However, the consolidated profit after tax turned into a loss of ₹0.74 crore, compared to a profit of ₹0.30 crore in FY2025.

On a standalone basis, revenue from operations grew by 27.7% to ₹8.52 crore. Despite this top-line growth, the company registered a standalone loss after tax of ₹0.65 crore, a shift from a standalone profit of ₹0.30 crore in FY2025.

Why this matters

The key takeaway for investors is the divergence between revenue growth and profitability. While the company managed to expand its top line significantly, it was unable to translate this into profit. The inclusion of a newly acquired subsidiary, HSDL Innovative Private Limited, for the first time in consolidated figures means direct year-on-year comparison of consolidated numbers is not applicable. The company also confirmed full utilization of its Initial Public Offering (IPO) proceeds.

The backstory

Hamps Bio Ltd operates in two main segments: trading of pharma products and manufacturing of freeze-dried products. The company had previously reported profits. The acquisition of HSDL Innovative Private Limited, completed on March 25, 2026, is a significant strategic move, and its financials are now part of the consolidated results.

What changes now

With the full consolidation of the subsidiary and the reporting of a loss despite revenue growth, investors will be closely watching the company's strategy to improve profitability. The utilization of IPO funds for the FMCG division's plant and machinery is also a development to monitor for future revenue streams.

Risks to watch

The primary risk is the company's inability to return to profitability, especially on a consolidated basis. Investors will need to assess the reasons for the loss despite revenue growth and the integration of the new subsidiary.

Peer comparison

Information on specific peers and their performance is not provided in this filing.

Context metrics (time-bound)

Standalone revenue from operations increased from ₹6.67 crore in FY2025 to ₹8.52 crore in FY2026.

Standalone profit after tax shifted from ₹0.30 crore in FY2025 to a loss of ₹(0.65) crore in FY2026.

What to track next

Investors should closely monitor future quarterly results to see if Hamps Bio can improve its bottom line and if the newly acquired subsidiary contributes positively to profitability. The performance of its pharma and freeze-dried product segments will also be crucial.